RAC 1.55% $1.31 race oncology ltd

Pillar 1 - FTO (new thread), page-48

  1. 11,249 Posts.
    lightbulb Created with Sketch. 29635
    KEYTRUDA 2020 Worldwide Sales Grew 30% to $14.4 Billion

    https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2020-financial-results/

    For comparison:

    KEYTRUDA 2019 Worldwide Sales Grew 55% to $11.1 Billion

    https://www.businesswire.com/news/h...-Quarter-and-Full-Year-2019-Financial-Results

    With Keytruda growth starting to taper off Merck will be very keen to look at RACE - particularly if Bisantrene can help improve efficacy of Keytruda. They will also be battling it out with BMS who have their own PD-1 drug OPDIVO.

    I will update the below when I have more data (and the time to update it). We may see analysts release 2027 forecasts.


    Screen Shot 2021-02-05 at 7.34.11 am.png

    Also - just found this stat from 2018. Opdivo sells for about USD $150K in the US.

    https://endpts.com/bristol-myers-wi...setting-precedent-for-checkpoint-wave-report/
    Last edited by wombat777: 05/02/21
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.31
Change
0.020(1.55%)
Mkt cap ! $217.2M
Open High Low Value Volume
$1.31 $1.31 $1.26 $71.25K 55.65K

Buyers (Bids)

No. Vol. Price($)
1 200 $1.27
 

Sellers (Offers)

Price($) Vol. No.
$1.31 5950 3
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
$1.31
  Change
0.020 ( 2.18 %)
Open High Low Volume
$1.30 $1.31 $1.26 10789
Last updated 15.59pm 26/04/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.